{"ATC Code":"N - Nervous system","Abbreviation":"","Aliases":["L-pentazocine","Pentazocin","Pentazocine, (-)-","Levopentazocine","Pentazocinum","Pentazocine, L-","(-)-Pentazocine","7488-49-5","dl-Pentazocine","cis-(-)-Pentazocine"],"Biological Half-Life":"2 to 3 hours","CAS":"359-83-1","ChEBI":"CHEBI:7982","ChEMBL":"CHEMBL560","ChemicalClasses":["phenidate"],"Chirality":"racemic","Classes":["Opioid"],"Color/Form":"WHITE TO VERY PALE TAN CRYSTALLINE POWDER","Decomposition":"When heated to decomposition it emits toxic fumes of nitroxides.","Dosing Info":[],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Analgesics, Opioid; Narcotics; Narcotic Antagonists; Opiates","Drug Indication":"For the relief of moderate to severe pain.","Drug Warnings":"REPEATED INJECTION INTO A SINGLE AREA CAN PRODUCE STERILE ABSCESS, ULCERATION, AND SCARRING OF THE SC TISSUE AND MUSCLE. IF LONG-TERM ADMIN IS REQUIRED AND ORAL PENTAZOCINE CANNOT BE UTILIZED, THE INTRAMUSCULAR ROUTE SHOULD BE EMPLOYED AND THE INJECTIO SITE ROTATED. /PENTAZOCINE LACTATE/","DrugClasses":["opioid"],"DurationOfAction":"","EINECS":"206-634-6","EliminationHalfLife":"2 to 3 hours","European Community (EC) Number":"206-634-6","FDA Pharmacological Classification":"RP4A60D26L","FullSalts":["Pentazocine hydrochloride"],"HMDB ID":"HMDB0014790","HeavyAtomCount":21,"Human Drugs":"Breast Feeding; Lactation; Milk, Human; Analgesics, Opioid; Narcotics; Narcotic Antagonists; Opiates","IUPACName":"(1R,9R,13R)-1,13-dimethyl-10-(3-methylbut-2-enyl)-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol","InChI":"InChI=1S/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1","InChIKey":"VOKSWYLNZZRQPF-GDIGMMSISA-N","MeSH Pharmacological Classification":"Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)","Melting Point":"145.4-147.2 °C","MolecularFormula":"C\u003csub\u003e19\u003c/sub\u003eH\u003csub\u003e27\u003c/sub\u003eNO","MolecularWeight":"285.4 g/mol","Odor":"ODORLESS OR ALMOST ODORLESS","Opticalactivity":"( + / - )","Pharmacodynamics":"Pentazocine is a potent analgesic which when administered orally in a 50 mg dose appears equivalent in analgesic effect to 60 mg (1 grain) of codeine. Onset of significant analgesia usually occurs between 15 and 30 minutes after oral administration, and duration of action is usually three hours or longer. Onset and duration of action and the degree of pain relief are related both to dose and the severity of pretreatment pain. Pentazocine weakly antagonizes the analgesic effects of morphine and meperidine; in addition, it produces incomplete reversal of cardiovascular, respiratory, and behavioral depression induced by morphine and meperidine. Pentazocine has about 1/50 the antagonistic activity of nalorphine. It also has sedative activity.","Physical Description":"Solid","PrevSalts":["hydrochloride"],"PubChemId":441278,"Record Description":["Pentazocine is a benzazocine.","Pentazocine is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Other substances substance.","The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)","Pentazocine is a Partial Opioid Agonist/Antagonist. The mechanism of action of pentazocine is as a Competitive Opioid Antagonist, and Partial Opioid Agonist.","Pentazocine is a synthetic opioid with both agonist and antagonist activity against opiate receptors which was previously used in oral and parenteral forms as an analgesic for moderate-to-severe pain. Currently, it is only available in tablet form in combination with either acetaminophen or naloxone. Pentazocine has not been linked to serum enzyme elevations during therapy or to clinically apparent liver injury.","Pentazocine is only found in individuals that have used or taken this drug. It is the first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)The preponderance of evidence suggests that pentazocine antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor.","The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)","Pentazocine is a benzazocine.","LiverTox|Analgesic|Moderate pain|Opiate"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Pentazocine","Name":"Pentazocine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q415793","Name":"Pentazocine","Sub":false},{"Link":"https://www.wikidata.org/wiki/Q27273533","Name":"(+)-Pentazocine","Sub":true}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB00652","Name":"Pentazocine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/441278","Name":"Pentazocine","Sub":false},{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/12259685","Name":"(+)-Pentazocine","Sub":true}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL560","Name":"Pentazocine","Sub":false},{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL60542","Name":"(+)-Pentazocine","Sub":true}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7982","Name":"Pentazocine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=359-83-1","Name":"Pentazocine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0014790","Name":"Pentazocine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C07421","Name":"Pentazocine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/RP4A60D26L","Name":"Pentazocine","Sub":false},{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/A2G9VU2P2J","Name":"(+)-Pentazocine","Sub":true}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID7023433","Name":"Pentazocine","Sub":false},{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID90870517","Name":"(+)-Pentazocine","Sub":true}]}],"Reported Fatal Dose":"Toxic pentazocine blood concentration: 200-500 ug/dL; Lethal pentazocine blood concentration: 1-2 mg/dL /From table/","SMILES":"C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C(C)C)C)C=C(C=C3)O","Salts":["hydrochloride"],"SaltsAcidCount":[1],"SaltsAmineCount":[1],"SaltsUNII":["A36BXO4PPX"],"Scheduling":[{"gov":"Australia","schedule":"S8 substance"},{"gov":"Brazil","schedule":"B1 substance"},{"gov":"Canada","schedule":"Schedule I substance"},{"gov":"Germany","schedule":"Anlage III substance"},{"gov":"United States","schedule":"Schedule IV substance"},{"gov":"United Kingdom","schedule":"Class B substance"},{"act":"Convention on Psychotropic Substances 1971","gov":"United Nations","schedule":"Schedule III drug"}],"Solubility":"White to pale cream colored, odorless crystalline powder; there are two forms melting at about 218 deg \u0026 254 °C, respectively; Sol 1 part in 30 parts of water, 1 part in 16 parts alcohol, 1 part in 4 parts chloroform; very slightly sol in acetone; practically insol in ether; 1% soln in water has a pH of 4 to 6 /Pentazocine hydrochloride/","Stability/Shelf Life":"STABLE IN LIGHT, HEAT (AMBIENT ROOM TEMP), \u0026 AIR.","StereoisomerRacemic":"(RS)-Pentazocine","Stereoisomers":["(+)-Pentazocine","(-)-Pentazocine","(-)-Pentazocine","(-)-Pentazocine"],"StereoisomersUNII":["A2G9VU2P2J","","",""],"StoreUNII":["768DQ5A5AI"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="131.46mm" version="1.2" viewBox="0 0 75.094 131.46" width="75.094mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#000000" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="132.0" stroke="none" width="76.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <path class="bond" d="M34.637 69.928l-.35 -.607l-14.072 6.109l1.051 1.819l1.051 1.818z" id="mol1bnd1" stroke="none"/>
                  
            <line class="bond" id="mol1bnd2" x1="34.462" x2="34.46" y1="69.625" y2="54.385"/>
                  
            <line class="bond" id="mol1bnd3" x1="34.46" x2="14.286" y1="54.385" y2="64.563"/>
                  
            <line class="bond" id="mol1bnd4" x1="14.286" x2="12.467" y1="64.563" y2="82.323"/>
                  
            <g class="bond" id="mol1bnd5">
                        
                <line x1="28.758" x2="12.467" y1="89.625" y2="82.323"/>
                        
                <line x1="26.328" x2="12.902" y1="91.208" y2="85.19"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd6" x1="28.758" x2="47.671" y1="89.625" y2="77.242"/>
                  
            <line class="bond" id="mol1bnd7" x1="34.462" x2="47.671" y1="69.625" y2="77.242"/>
                  
            <line class="bond" id="mol1bnd8" x1="47.671" x2="60.878" y1="77.242" y2="69.62"/>
                  
            <line class="bond" id="mol1bnd9" x1="60.878" x2="60.876" y1="69.62" y2="54.38"/>
                  
            <line class="bond" id="mol1bnd10" x1="60.876" x2="50.82" y1="54.38" y2="48.581"/>
                  
            <path class="bond" d="M34.285 54.081l.349 .607l10.72 -4.649l-.841 -1.457l-.841 -1.457z" id="mol1bnd11" stroke="none"/>
                  
            <line class="bond" id="mol1bnd12" x1="47.666" x2="47.664" y1="42.913" y2="31.522"/>
                  
            <line class="bond" id="mol1bnd13" x1="47.664" x2="60.861" y1="31.522" y2="23.9"/>
                  
            <g class="bond" id="mol1bnd14">
                        
                <line x1="60.861" x2="60.858" y1="23.9" y2="8.66"/>
                        
                <line x1="58.422" x2="58.42" y1="22.493" y2="10.069"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd15" x1="60.858" x2="74.055" y1="8.66" y2="1.038"/>
                  
            <line class="bond" id="mol1bnd16" x1="60.858" x2="47.659" y1="8.66" y2="1.042"/>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="47.969" x2="47.373" y1="77.059" y2="77.426"/>
                        
                <line x1="49.549" x2="48.456" y1="79.069" y2="79.742"/>
                        
                <line x1="51.128" x2="49.538" y1="81.08" y2="82.058"/>
                        
                <line x1="52.708" x2="50.621" y1="83.091" y2="84.374"/>
                        
                <line x1="54.287" x2="51.703" y1="85.101" y2="86.691"/>
                        
                <line x1="55.866" x2="52.786" y1="87.112" y2="89.007"/>
                        
                <line x1="57.446" x2="53.868" y1="89.122" y2="91.323"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="28.758" x2="28.843" y1="89.625" y2="104.838"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="16.553" x2="28.843" y1="113.198" y2="104.838"/>
                        
                <line x1="16.308" x2="26.397" y1="110.416" y2="103.552"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="16.553" x2="2.99" y1="113.198" y2="107.119"/>
                  
            <g class="bond" id="mol1bnd21">
                        
                <line x1="1.054" x2="2.99" y1="92.382" y2="107.119"/>
                        
                <line x1="3.641" x2="5.23" y1="93.352" y2="105.451"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd22" x1="12.467" x2="1.054" y1="82.323" y2="92.382"/>
                  
            <line class="bond" id="mol1bnd23" x1="16.553" x2="17.547" y1="113.198" y2="124.463"/>
                  
            <path class="atom" d="M49.607 49.212h-.72l-2.62 -4.066h-.029q.011 .238 .029 .595q.024 .358 .024 .733v2.738h-.565v-4.899h.714l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" id="mol1atm10" stroke="none"/>
                  
            <g class="atom" id="mol1atm21">
                        
                <path d="M20.152 128.376q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM16.288 128.376q.0 .923 .387 1.459q.393 .53 1.221 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q.0 -.928 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.227 .524q-.393 .524 -.393 1.452z" fill="#FF0D0D" stroke="none"/>
                        
                <path d="M24.458 130.829h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.071h2.512v-2.071h.619v4.899z" fill="#FF0D0D" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd10" stroke="#3050F8" x1="50.82" x2="55.848" y1="48.581" y2="51.480500000000006"/>
            <line class="hi" id="mol1bnd12" stroke="#3050F8" x1="47.666" x2="47.665" y1="42.913" y2="37.2175"/>
            <line class="hi" id="mol1bnd23" stroke="#FF0D0D" x1="17.547" x2="17.05" y1="124.463" y2="118.8305"/>
        </g>
          
    </g>
    
</svg>
","Taste":"SLIGHTLY BITTER TASTE","Therapeutic Uses":"Adjuvants, Anesthesia; Analgesics, Opioid; Narcotic Antagonists; Narcotics","Title":"Pentazocine","UNII":"RP4A60D26L","Wikidata":"Q415793","Wikipedia":"Pentazocine","XLogP":3.3}